Molecular structure of Ursodeoxycholic acid, CAS Number: 128-13-2
Ursodeoxycholic acid (CAS 128-13-2)
See product citations (4)
Application:
Ursodeoxycholic acid is a bile acid with significant colon chemopreventive activity
CAS Number:
128-13-2
Purity:
≥97%
Molecular Weight:
392.57
Molecular Formula:
C24H40O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ursodeoxycholic acid is a bile acid that naturally occurs in the body and plays a vital role in fat digestion within the digestive system. Its mechanism of action involves several pathways. Firstly, it is believed to inhibit the absorption of cholesterol in the intestine, thereby reducing the amount of cholesterol taken up by the body. Additionally, Ursodeoxycholic acid decreases the liver′s production of bile acids, which contributes to a decrease in cholesterol synthesis. Moreover, it enhances the solubility of cholesterol in bile, preventing its precipitation and the formation of gallstones. Ursodeoxycholic acid may also stimulate the liver to produce more bile acids and promote the secretion of bile acids into the intestine, facilitating the digestion and absorption of fats.
Ursodeoxycholic acid (CAS 128-13-2) References
- Ursodeoxycholic acid action on the transport function of the small intestine in normal and cystic fibrosis mice. | Hardcastle, J., et al. 2001. J Pharm Pharmacol. 53: 1457-67. PMID: 11732748
- Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. | Willart, MA., et al. 2012. Allergy. 67: 1501-10. PMID: 23004356
- Ursodeoxycholic acid pretreatment reduces oral bioavailability of the multiple drug resistance-associated protein 2 substrate baicalin in rats. | Wu, T., et al. 2013. Planta Med. 79: 1615-9. PMID: 24135887
- Ursodeoxycholic acid alleviates cholestasis-induced histophysiological alterations in the male reproductive system of bile duct-ligated rats. | Saad, RA. and Mahmoud, YI. 2014. Reprod Toxicol. 50: 87-97. PMID: 25461907
- Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary? | Akdemir, A., et al. 2015. Arch Gynecol Obstet. 292: 445-50. PMID: 25663134
- Ursodeoxycholic acid impairs atherogenesis and promotes plaque regression by cholesterol crystal dissolution in mice. | Bode, N., et al. 2016. Biochem Biophys Res Commun. 478: 356-362. PMID: 27416761
- Ursodeoxycholic acid lowers bile lithogenicity by regulating SCP2 expression in rabbit cholesterol gallstone models. | Cui, Y., et al. 2012. EXCLI J. 11: 593-603. PMID: 27847447
- A facile synthesis of ursodeoxycholic acid and obeticholic acid from cholic acid. | He, XL., et al. 2018. Steroids. 140: 173-178. PMID: 30389306
- Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. | Simental-Mendía, LE., et al. 2019. Lipids Health Dis. 18: 88. PMID: 30954082
- Ursodeoxycholic Acid (UDCA) Promotes Lactate Metabolism in Mouse Hepatocytes through Cholic Acid (CA) - Farnesoid X Receptor (FXR) Pathway. | Wang, L., et al. 2020. Curr Mol Med. 20: 661-666. PMID: 31971110
- Ursodeoxycholic acid protects neonatal rats from necrotizing enterocolitis: a biochemical, histopathological, and immunohistochemical study. | Sönmezgöz, E., et al. 2021. J Matern Fetal Neonatal Med. 34: 3761-3767. PMID: 32954879
- Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. | Xie, P., et al. 2022. Carbohydr Polym. 288: 119388. PMID: 35450649
- Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis. | Lin, X., et al. 2022. Expert Rev Gastroenterol Hepatol. 16: 537-545. PMID: 35617696
- Role of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a systematic review and meta-analysis of randomized controlled trials. | Lazarus, G., et al. 2022. Ital J Pediatr. 48: 179. PMID: 36253867
Inhibitor of:
AAT-1, ABCG5, CdcA3, Gastrokine 2, HNF-3α, Mdr-3, OSTα, OSTβ, PDC-E2, PEMT, Peroxin 5, Rotavirus capsid, SCD3, SCD4, and VAP-1.Activator of:
ABCG5, AKR1CL2, Arylsulfatase, Asbt, ATP8B1, BAAT, BSDC1, BSEP, colipase, CYP24, CYP27A1, Cyp4f17, CYP8B1, DR3, EG435927, EG619597, FIC1, FXR, Glutamate-Pyruvate Transaminase, Hepassocin, Mdr-2, MRP2, NPC1L1, Oatp5, OSTβ, P504S (AMACR), PLRP1, PLRP2, Prothrombin, Retnlb, SCP-2, SerpinA1e, SLC10A6, Sodium Taurochenodeoxycholate, Stabilin-1, and TGR5.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ursodeoxycholic acid, 1 g | sc-204935 | 1 g | $51.00 | |||
Ursodeoxycholic acid, 5 g | sc-204935A | 5 g | $128.00 |